Asian Pacific Journal of Cancer Prevention

  • 제16권10호
  • /
  • Pages.4347-4351
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer

  • Yuan, Zhi-Jun (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Zhou, Wen-Wu (Department of Thoracic Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University) ;
  • Liu, Wei (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Wu, Bai-Ping (Molecular Biology Laboratory, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Zhao, Jin (Molecular Biology Laboratory, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Wu, Wei (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • He, Yi (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Yang, Shuo (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Su, Jing (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University) ;
  • Luo, Yi (Medical Department of Veteran Cadre, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University)
  • 발행 : 2015.06.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Previous studies showed that genetic polymorphisms of glutathione S-transferase P1 (GSTP1) were involved in glutathione metabolism and genetic polymorphisms of ribonucleotide reductase (RRM1) were correlated with DNA synthesis. Here we explored the effects of these polymorphisms on the chemosensitivity and clinical outcome in Chinese non-small cell lung cancer (NSCLC) patients treated with gemcitabine-cisplatin regimens. Materials and Methods: DNA sequencing was used to evaluate genetic polymorphisms of GSTP1 Ile105Val and RRM1 C37A-T524C in 47 NSCLC patients treated with gemcitabine-cisplatin regimens. Clinical response was evaluated according to RECIST criteria after 2 cycles of chemotherapy and toxicity was assessed by 1979 WHO criteria (acute and subacute toxicity graduation criteria in chemotherapeutic agents). Results: There was no statistical significance between sensitive and non-sensitive groups regarding the genotype frequency distribution of GSTP1 Ile105Val polymorphism (p>0.05). But for RRM1 C37A-T524C genotype, sensitive group had higher proportion of high effective genotype than non-sensitive group (p=0.009). And according to the joint detection of GSTP1 Ile105Val and RRM1 C37A-T524C polymorphisms, the proportion of type A (A/A + high effective genotype) was significantly higher in sensitive group than in non-sensitive group (p=0.009). Toxicity showed no correlation with the genotypes between two groups (p>0.05). Conclusions: Compared with single detection of genetic polymorphisms of GSTP1 Ile105Val or RRM1 C37A-T524C, joint detection of both may be more helpful for patients with NSCLC to receive gemcitabine-cisplatin regimens as the first-line chemotherapy. Especially, genetic polymorphism of RRM1 is more likely to be used as an important biomarker to predict the response and toxicity of gemcitabine-cisplatin combination chemotherapy in NSCLC.

키워드

참고문헌

  1. Allen WL, Johnston PG (2005). Role of genomic markers in colorectal cancer treatment. J Clin Oncol, 23, 4545-52. https://doi.org/10.1200/JCO.2005.19.752
  2. Booton R, Ward T, Heighway J, et al (2006). Glutathione-Stransferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol, 1, 679-83. https://doi.org/10.1097/01243894-200609000-00013
  3. Chu T, Bunce K, Hogge WA, et al (2009). Statistical model for whole genome sequencing and its application to minimally invasive diagnosis of fetal genetic disease. Bioinformatics, 25, 1244-50. https://doi.org/10.1093/bioinformatics/btp156
  4. De Luca A, Pellizzari Tregno F, Sau A, et al (2013). Glutathione S-transferase P1-1 as a target for mesothelioma treatment. Cancer Sci, 104, 223-30. https://doi.org/10.1111/cas.12061
  5. Dong X, Hao Y, Wei Y, et al (2014). Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS One, 9, 92320. https://doi.org/10.1371/journal.pone.0092320
  6. Fuertes MA, Castilla J, Alonso C, et al (2003). Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem, 10, 257-66. https://doi.org/10.2174/0929867033368484
  7. Gray J, Simon G, Bepler G (2007). Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther, 7, 545-9. https://doi.org/10.1586/14737140.7.4.545
  8. Kabler SL, Seidel A, Jacob J, et al (2009). Differential protection by human glutathione S-transferase P1 against cytotoxicity of benzo[a]pyrene, dibenzo[a,l]pyrene, or their dihydrodiol metabolites, in bi-transgenic cell lines that co-express rat versus human cytochrome P4501A1. Chem Biol Interact, 179, 240-6. https://doi.org/10.1016/j.cbi.2009.01.010
  9. Li Y, Wang LR, Chen J, et al (2014). First-line gemcitabine plus cisplatin in non-small cell lung cancer patients. Dis Markers, 2014, 960458.
  10. Lu C, Spitz MR, Zhao H, et al (2006). Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced non-small cell lung carcinoma. Cancer, 106, 441-7. https://doi.org/10.1002/cncr.21619
  11. Lv HY, Li QC, Wei HJ, et al (2012). Relationship between GSTP1 and XPG genetic polymorphisms and survival of platinum-based chemotherapy in advanced non-small cell lung cancer patients. China Oncology, 22, 609-17.
  12. Nakahira S, Nakamori S, Tsujie M, et al (2007). Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer, 120, 1355-63. https://doi.org/10.1002/ijc.22390
  13. Ou C, Zhu B, Zhao HL, et al (2015). Association of glutathione S-transferase P1 gene polymorphism with the risk of smallcell carcinoma of lungcancer. J Recept Signal Transduct Res, 35, 165-9. https://doi.org/10.3109/10799893.2014.942463
  14. Parker LJ, Italiano LC, Morton CJ, et al (2011). Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation. Chemistry, 17, 7806-16. https://doi.org/10.1002/chem.201100586
  15. Peklak-Scott C, Smitherman PK, Townsend AJ, et al (2008). Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther, 7, 3247-55. https://doi.org/10.1158/1535-7163.MCT-08-0250
  16. Qiu ZQ, Zhao K (2014). Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. Asian Pac J Cancer Prev, 15, 7303-7. https://doi.org/10.7314/APJCP.2014.15.17.7303
  17. Rodriguez J, Boni V, Hernández A, et al (2011). Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. Eur J Cancer, 47, 839-47. https://doi.org/10.1016/j.ejca.2010.11.032
  18. Sharma R, Ellis B, Sharma A (2011). Role of alpha class glutathione transferases (GSTs) in chemoprevention: GSTA1 and A4 overexpressing human leukemia (HL60) cells resist sulforaphane and curcumin induced toxicity. Phytother Res, 25, 563-8. https://doi.org/10.1002/ptr.3297
  19. Singh S (2015). Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol, 75, 1-15. https://doi.org/10.1007/s00280-014-2566-x
  20. Sun N, Sun X, Chen B, et al (2010). MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol, 65, 437-46. https://doi.org/10.1007/s00280-009-1046-1
  21. Wang LR, Huang MZ, Zhang GB, et al (2007). Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 60, 601-7. https://doi.org/10.1007/s00280-007-0504-x
  22. Wang L, Wu X, Huang M, et al (2007). The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 60, 211-8. https://doi.org/10.1007/s00280-006-0363-x
  23. Zhang GB, Chen J, Wang LR, et al (2012). RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. Cancer Chemother Pharmacol, 69, 1277-87. https://doi.org/10.1007/s00280-012-1834-x
  24. Zhang X, Jin FS, Zhang LG, et al (2013). Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a metaanalysis. Asian Pac J Cancer Prev, 14, 4261-5. https://doi.org/10.7314/APJCP.2013.14.7.4261
  25. Zhang Y, Yu L, Xia N (2014). Effect of Brucea Javanica Oil Emulsion combined with GP regimen on the immune function of patients with advanced non-small cell lung cancer. J Int Transl Med, 2, 262-5.
  26. Zhou F, Yu Z, Jiang T, et al (2011). Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkl, 141, 13275.

피인용 문헌

  1. The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy vol.141, pp.11, 2017, https://doi.org/10.1002/ijc.30921
  2. Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-02833-7
  3. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-05642-0
  4. Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis pp.1724-6008, 2018, https://doi.org/10.1177/1724600818792897
  5. Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review vol.9, pp.1663-9812, 2018, https://doi.org/10.3389/fphar.2018.01111